SLC22A2 and nephrosclerosis: Although most cases in this study showed a decrease in serum creatinine with TFR, its increase during bosutinib treatment might not only be an apparent increase because of bosutinib's inhibition of tubular OCT2, but also owing to renal damage caused by previously used TKIs and concomitant drugs and nephrosclerosis caused by aging and complications.